MARKET NEWS

Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin 
Onconova Therapeutics Provides Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment to Improve Overall Lung Health
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi 
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency
Idorsia Ltd Announces the Initiation of Phase 3 Registration Study of Antithrombotic Treatment for Use at the Onset of AMI Symptoms

  FEATURED EDITORIAL

  COMPANY PROFILE

Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square-foot GMP facility in Boonton, New Jersey, offering an expanding range of manufacturing and development services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH). Since its founding in 2013, Enteris has advanced into the clinic multiple internal and external programs leveraging its Peptelligence platform. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Lonza Invests to Expand Mid-Scale Small Molecule Production Capacity, HPAPI Production at Nansha, China, Facility

Lonza Invests to Expand Mid-Scale Small Molecule Production Capacity, HPAPI Production at Nansha, China, Facility

To help pharma and biotech companies scale up production rapidly and effectively, Swiss CDMO Lonza recently announced an investment of CHF 20 million to bring flexible, mid-scale manufacturing capabilities to its API….

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study

Crinetics Pharmaceuticals, Inc. recently announced the randomization of the first acromegaly patient in its Phase 3 clinical trial of paltusotine, PATHFNDR-1. This trial will be one of two planned Phase 3 studies assessing….

Roquette Boosts Customer Support With New Digital Pharma Marketplace

Roquette Boosts Customer Support With New Digital Pharma Marketplace

Roquette recently announced the opening of its new pharma online marketplace, powered by Knowde. The e-commerce platform will provide users….

Agios Submits MAA to EMA for Mitapivat for Treatment of Adults With Pyruvate Kinase Deficiency

Agios Submits MAA to EMA for Mitapivat for Treatment of Adults With Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. recently announced it has submitted a Marketing Authorization Application (MAA) for mitapivat to the European Medicines Agency (EMA) for the treatment of adults with pyruvate kinase….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 21 – Bioavailability
July 28 – Excipients